百时美施贵宝
BMY54.670USD
-0.040-0.07%
收盘 12/26, 16:00（美东）报价延迟15分钟
111.31B总市值
18.40市盈率 TTM
关于 百时美施贵宝 公司
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
百时美施贵宝简介
公司代码BMY
公司名称Bristol-Myers Squibb Co
上市日期Mar 17, 1980
CEOBoerner (Christopher S)
员工数量34100
证券类型Ordinary Share
年结日Mar 17
公司地址Route 206 And Province Line Road
城市PRINCETON
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编08543
电话16092524621
网址https://www.bms.com
公司代码BMY
上市日期Mar 17, 1980
CEOBoerner (Christopher S)
百时美施贵宝公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
63.90K
+1.88%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
19.77K
+18.37%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
11.07K
+25.18%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Dr. Deepak L. Bhatt, M.D.
Dr. Deepak L. Bhatt, M.D.
Independent Director
Independent Director
--
--
Mr. Phil Holzer
Mr. Phil Holzer
Senior Vice President, Controller
Senior Vice President, Controller
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
63.90K
+1.88%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
19.77K
+18.37%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
11.07K
+25.18%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Eliquis
3.68B
30.00%
Opdivo
2.59B
21.09%
Orencia
963.00M
7.85%
Revlimid
838.00M
6.83%
Yervoy
728.00M
5.93%
其他
3.47B
28.29%
地区USD
名称
营收
占比
United States
8.52B
69.44%
International
3.48B
28.37%
other
270.00M
2.20%
业务
地区
业务USD
名称
营收
占比
Eliquis
3.68B
30.00%
Opdivo
2.59B
21.09%
Orencia
963.00M
7.85%
Revlimid
838.00M
6.83%
Yervoy
728.00M
5.93%
其他
3.47B
28.29%
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.58%
BlackRock Institutional Trust Company, N.A.
4.98%
State Street Investment Management (US)
4.74%
Charles Schwab Investment Management, Inc.
3.59%
JP Morgan Asset Management
2.90%
其他
74.21%
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.58%
BlackRock Institutional Trust Company, N.A.
4.98%
State Street Investment Management (US)
4.74%
Charles Schwab Investment Management, Inc.
3.59%
JP Morgan Asset Management
2.90%
其他
74.21%
股东类型
持股股东
占比
Investment Advisor
44.02%
Investment Advisor/Hedge Fund
25.70%
Research Firm
2.97%
Pension Fund
2.51%
Hedge Fund
2.51%
Bank and Trust
2.22%
Sovereign Wealth Fund
1.74%
Insurance Company
0.19%
Family Office
0.06%
其他
18.08%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
3973
1.68B
84.73%
-171.91K
2025Q3
4147
1.68B
85.10%
-5.79M
2025Q2
4212
1.69B
83.90%
+15.56M
2025Q1
4284
1.67B
82.20%
-238.41K
2024Q4
4280
1.64B
80.20%
+45.34M
2024Q3
4106
1.59B
79.76%
+6.69M
2024Q2
4097
1.58B
82.24%
-51.64M
2024Q1
4107
1.64B
80.22%
+12.13M
2023Q4
4104
1.60B
80.80%
-21.68M
2023Q3
4025
1.62B
80.17%
-24.04M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
193.94M
9.53%
+3.47M
+1.82%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
99.37M
4.88%
+1.60M
+1.64%
Jun 30, 2025
State Street Investment Management (US)
94.74M
4.65%
-94.48K
-0.10%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
70.80M
3.48%
+10.20M
+16.82%
Jun 30, 2025
JP Morgan Asset Management
67.41M
3.31%
-2.47M
-3.54%
Jun 30, 2025
Geode Capital Management, L.L.C.
46.18M
2.27%
+723.46K
+1.59%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
33.57M
1.65%
-1.60M
-4.55%
Jun 30, 2025
Capital International Investors
66.16M
3.25%
-303.34K
-0.46%
Jun 30, 2025
Columbia Threadneedle Investments (US)
29.38M
1.44%
+350.53K
+1.21%
Jun 30, 2025
PRIMECAP Management Company
22.94M
1.13%
-25.98K
-0.11%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月5日 周五
更新时间: 12月5日 周五
机构名称
占比
VanEck Pharmaceutical ETF
9.15%
First Trust NASDAQ Pharmaceuticals ETF
7.58%
Franklin US Dividend Booster Index ETF
5.08%
WBI Power Factor High Dividend ETF
4.88%
VanEck Morningstar Wide Moat Value ETF
4.34%
iShares U.S. Pharmaceuticals ETF
4.31%
Schwab U.S. Dividend Equity ETF
3.74%
ETC 6 Meridian Hedged Equity Index Option ETF
3.68%
ETC 6 Meridian Mega Cap Equity ETF
3.58%
Brookstone Value Stock ETF
3.48%
查看更多
VanEck Pharmaceutical ETF
占比9.15%
First Trust NASDAQ Pharmaceuticals ETF
占比7.58%
Franklin US Dividend Booster Index ETF
占比5.08%
WBI Power Factor High Dividend ETF
占比4.88%
VanEck Morningstar Wide Moat Value ETF
占比4.34%
iShares U.S. Pharmaceuticals ETF
占比4.31%
Schwab U.S. Dividend Equity ETF
占比3.74%
ETC 6 Meridian Hedged Equity Index Option ETF
占比3.68%
ETC 6 Meridian Mega Cap Equity ETF
占比3.58%
Brookstone Value Stock ETF
占比3.48%
分红派息
近5年累计派现
22.71B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Dec 10, 2025
BMY.NB Interim Cash Dividend of gross USD 0.63 paid on Feb 02, 2026 going ex on Jan 02, 2026 with reinvestment option
Jan 02, 2026
Feb 02, 2026
Jan 02, 2026
Sep 17, 2025
BMY.NB Final Cash Dividend of gross USD 0.62 paid on Nov 03, 2025 going ex on Oct 03, 2025 with reinvestment option
Oct 03, 2025
Nov 03, 2025
Oct 03, 2025
Jun 17, 2025
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Aug 01, 2025 going ex on Jul 03, 2025 with reinvestment option
Jul 03, 2025
Aug 01, 2025
Jul 03, 2025
Mar 03, 2025
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on May 01, 2025 going ex on Apr 04, 2025 with reinvestment option
Apr 04, 2025
May 01, 2025
Apr 04, 2025
Dec 11, 2024
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option
Jan 03, 2025
Feb 03, 2025
Jan 03, 2025
Sep 10, 2024
BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option
Oct 04, 2024
Nov 01, 2024
Oct 04, 2024
Jun 18, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option
Jul 05, 2024
Aug 01, 2024
Jul 05, 2024
Mar 01, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option
Apr 05, 2024
May 01, 2024
Apr 04, 2024
Dec 06, 2023
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option
Jan 05, 2024
Feb 01, 2024
Jan 04, 2024
Sep 20, 2023
BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023
Oct 06, 2023
Nov 01, 2023
Oct 05, 2023
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
百时美施贵宝的前五大股东是谁？
百时美施贵宝 的前五大股东如下：
The Vanguard Group, Inc.持有股份：193.94M，占总股份比例：9.53%。
BlackRock Institutional Trust Company, N.A.持有股份：99.37M，占总股份比例：4.88%。
State Street Investment Management (US)持有股份：94.74M，占总股份比例：4.65%。
Charles Schwab Investment Management, Inc.持有股份：70.80M，占总股份比例：3.48%。
JP Morgan Asset Management持有股份：67.41M，占总股份比例：3.31%。
The Vanguard Group, Inc.持有股份：193.94M，占总股份比例：9.53%。
BlackRock Institutional Trust Company, N.A.持有股份：99.37M，占总股份比例：4.88%。
State Street Investment Management (US)持有股份：94.74M，占总股份比例：4.65%。
Charles Schwab Investment Management, Inc.持有股份：70.80M，占总股份比例：3.48%。
JP Morgan Asset Management持有股份：67.41M，占总股份比例：3.31%。
百时美施贵宝的前三大股东类型是什么？
百时美施贵宝 的前三大股东类型分别是：
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
有多少机构持有百时美施贵宝(BMY)的股份？
截至2025Q4，共有3973家机构持有百时美施贵宝的股份，合计持有的股份价值约为1.68B，占公司总股份的84.73%。与2025Q3相比，机构持股有所增加，增幅为-0.37%。
哪个业务部门对百时美施贵宝的收入贡献最大？
在FY2025Q2，Eliquis业务部门对百时美施贵宝的收入贡献最大，创收3.68B，占总收入的30.00%。
